Sickle Cell Warriors

Tag "news"

    GBT’s Phase 3 HOPE study Results

GBT’s Phase 3 HOPE study Results

GBT Announces Positive Top-line Data from Part A of the Phase 3 HOPE Study of Voxelotor in Sickle Cell Disease Primary Endpoint Achieved; 58 Percent of Patients on Voxelotor Dosed with 1500 mg at Week 12 Exceeded 1 g/dL Increase in Hemoglobin Versus 9 Percent of Placebo (p<0.0001) Company Met

0 comment Read Full Article

Donate

Support awareness & education for SCD

WordPress › Error

Error! Donation amount must be a numeric value.